---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-180722"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:13:40.378251+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytomX raises $30M via private placement of units with warrants

## Summary
- Gross proceeds of $30M from unit sale at $2.08 each; closing expected July 3, 2023.
- Each unit: 1 share or Pre-Funded Warrant ($0.00001 exercise, 20-yr term) plus Tranche 1 ($4.16, exp. 2025) and Tranche 2 ($6.24, exp. 2026) warrants.
- No underwriter; resale registration statement to be filed within 60 days after closing.
- Pre-funded and Tranche warrants may not be exercised if holder would exceed 9.99% ownership (adjustable to 19.99%).
- Exercise price of Tranche warrants subject to reset if future offering below $4.16, but not below $2.08.

## SEC filing metadata
- accession: 0001193125-23-180722
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312523180722/0001193125-23-180722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312523180722/d500160d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-180722
- JSON: https://secwatch.observer/filing/0001193125-23-180722.json
- Plain text: https://secwatch.observer/filing/0001193125-23-180722.txt

## Key facts
- Material Agreements
  CytomX Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $30.0 million (effective 2023-06-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $30.0 million
  - Effective: 2023-06-29
  source text: On June 29, 2023, CytomX Therapeutics, Inc. (the “Company”) entered into a unit purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000119312523180722/0001193125-23-180722-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.